Novo Nordisk (NVO) aims to start selling its weight-loss blockbuster Wegovy in vials, its latest move to win over customers it’s lost to rival Eli Lilly & Co. (LLY), Bloomberg News reported.
Currently Novo sells the drug in plastic injector pens.
Rival Lilly launched vials nearly two years ago to offer a lower-priced version of its shot and alleviate shortages. It’s unclear what Novo (NVO) will charge for vials, but the company has already been aggressively discounting its obesity drugs to compete, the report added.
Lilly (LLY) last year cut the price for vials of Zepbound by $50 or more and expanded the range of doses sold online.